Efficacy of antiviral agents against the SARS-CoV-2 omicron subvariant BA.2 was written by Takashita, Emi;Kinoshita, Noriko;Yamayoshi, Seiya;Sakai-Tagawa, Yuko;Fujisaki, Seiichiro;Ito, Mutsumi;Iwatsuki-Horimoto, Kiyoko;Halfmann, Peter;Watanabe, Shinji;Maeda, Kenji;Imai, Masaki;Mitsuya, Hiroaki;Ohmagari, Norio;Takeda, Makoto;Hasegawa, Hideki;Kawaoka, Yoshihiro. And the article was included in New England Journal of Medicine in 2022.Reference of 2492423-29-5 The following contents are mentioned in the article:
The omicron (B.1.1.529) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is responsible for coronavirus disease 2019 (Covid-19), has spread rapidly around the world and has already become the predominant variant circulating in many countries. As compared with the Wuhan/Hu-1/2019 reference strain, the sublineage BA.2 of the omicron variant has 16 amino acid substitutions in the receptor-binding domain of the spike (S) protein of SARS-CoV-2, which is the primary target for monoclonal antibody-based therapy. These findings suggest that there may be differences in the effectiveness of monoclonal antibodies against these different omicron sub-lineages. The susceptibilities of omicron/BA.2 (NCD1288) to remdesivir, molnupiravir, and nirmatrelvir were similar to those of the ancestral strain and other variants of concern (i.e., 50% inhibitory concentration values for these three agents that differed by factors of 2.5 to 4.5, 0.7 to 1.6, and 1.5 to 3.3, resp.). Clin. studies are warranted to determine whether these antiviral therapies are indeed effective against omicron/BA.2 infections. Our data indicate that some therapeutic monoclonal antibodies (REGN10987-REGN10933, COV2-2196-COV2-2130, and S309) have lower neutralizing activity against omicron/BA.2 than against earlier variant strains. This study involved multiple reactions and reactants, such as ((2R,3S,4R,5R)-3,4-Dihydroxy-5-((Z)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate (cas: 2492423-29-5Reference of 2492423-29-5).
((2R,3S,4R,5R)-3,4-Dihydroxy-5-((Z)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate (cas: 2492423-29-5) belongs to tetrahydrofuran derivatives. Tetrahydrofuran (THF), or oxolane, is mainly used as a precursor to polymers. Being polar and having a wide liquid range, THF is a versatile solvent. THF (Tetrahydrofuran) is also used as a starting material for the synthesis of poly(tetramethylene ether) glycol (PTMG), etc.Reference of 2492423-29-5
Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem